soul trial oral semaglutide cardiovascular outcomes 2024 results nejm Reduces CV Events in T2DM โ (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine ๐งช T2DM + ASCVD/CKD ๐ Oral semaglutide 14 mg vs placebo ๐ Oral Semaglutide and Cardiovascular Outcomes
Description
Clinical efficacy depends on the semaglutide molecule itself, not the brand name
Areas we serve
Glutamine links obesity to inflammation in human white adipose tissue
Safety Considerations and Side Effects GLP-1 agonists are generally well-tolerated, with common side effects including nausea, vomiting, and diarrhea, especially during the initial stages of treatment
Our patience shall be rewarded
To get started on your journey to achieving your weight loss goals and improving your wellness, schedule your initial consultation session at our clinic
